(gene therapy) OR (cell therapy)

	NCT Number	Title	Authors	Description	Identifier	Dates
1	pubmed:36095849	Efficacy and safety of cilta-cel in patients with progressive MM after exposure to other BCMA-targeting agents	Adam D Cohen Maria-Victoria Mateos Yael C Cohen Paula Rodriguez-Otero Bruno Paiva Niels W C J van de Donk Thomas G Martin Attaya Suvannasankha Kevin C De Braganca Christina Corsale Jordan M Schecter Helen Varsos William Deraedt Liwei Wang Martin Vogel Tito Roccia Xiaoying Xu Pankaj Mistry Enrique Zudaire Muhammad Akram Tonia Nesheiwat Lida Pacaud Irit Avivi Jesus San-Miguel	B-cell maturation antigen (BCMA)-targeting therapies, including bispecific antibodies (BsAbs) and antibody-drug conjugates (ADC), are promising treatments for multiple myeloma (MM), but disease may progress after their use. CARTITUDE-2 is a phase 2, multicohort study evaluating the safety and efficacy of cilta-cel, an anti-BCMA chimeric antigen receptor T therapy, in various myeloma patient populations. Patients in cohort C progressed despite treatment with a proteasome inhibitor,...	pmid:36095849 doi:10.1182/blood.2022015526	Mon, 12 Sep 2022 06:00:00 -0400
2	pubmed:36095964	Attenuated Salmonella Typhimurium with truncated LPS and outer membrane-displayed RGD peptide for cancer therapy	Kang Liang Zhenyuan Tian Xin Chen Mengru Li Xiaofen Zhang Xiaoping Bian Md Kaisar Ali Qingke Kong	Gram-negative, facultatively anaerobic bacteria Salmonella Typhimurium is a candidate agent or delivery vector for cancer therapy. Effective targeted therapies in addition to radiotherapy, chemotherapy and surgery have been urgently needed as an alternative or supplement. This study expected to further improve the tumor-targeting ability of Salmonella bacteria through genetic modifications. Based on an auxotrophic Salmonella bacterial strain (D2), we constructed Salmonella mutants with altered...	pmid:36095964 doi:10.1016/j.biopha.2022.113682	Mon, 12 Sep 2022 06:00:00 -0400
3	pubmed:36096011	Sublobar resection without staging and lymphadenectomy for 2 cm Non-Small Cell Lung Cancer is no adequate therapy	Georg Schlachtenberger Fabian Doerr Hruy Menghesha Lars Hagmeyer Gerardus Bennink Christopher Gaisendrees Thorsten Wahlers Khosro Hekmat Matthias B Heldwein	CONCLUSION: 16.5% of patients with 2 cm NSCLC were nodal upstaged postoperatively. These results underline that lymphadenectomy and proper staging are crucial for NSCLC patients irrespective of the tumor size and the surgical approach.	pmid:36096011 doi:10.1016/j.suronc.2022.101840	Mon, 12 Sep 2022 06:00:00 -0400
4	pubmed:36096032	Udder health, veterinary costs, and antibiotic usage in free stall compared with tie stall dairy housing systems: An optimized matching approach in Switzerland	Armin van Aken Daniel Hoop Katharina Friedli Stefan Mann	Observational studies are important in livestock science. As treatment is not assigned randomly in such studies, selection bias can be a problem. This is often addressed by matching methods. However, if treatment and control groups differ considerably in their characteristics, it might be necessary to additionally prune observations that lack overlap in the opposite group. "Matching Frontier" method was developed because pruning observations manually often results in suboptimal solutions. The...	pmid:36096032 doi:10.1016/j.rvsc.2022.08.021	Mon, 12 Sep 2022 06:00:00 -0400

	NCT Number	Title	Authors	Description	Identifier	Dates
5	pubmed:36096040	Survival trends in solid cancers in the Nordic countries through 50 years	Janne Hemminki Asta Försti Akseli Hemminki Kari Hemminki	CONCLUSIONS: The analysis over a half-century confirms the progress in 'real-world' cancer control, and in 84% of patients 5-year survival was >60%. Metastases remain a challenge, placing the emphasis on early detection before metastasis occurs. Novel therapies, such as immunotherapy which has curative potential even against metastatic disease, are needed.	pmid:36096040 doi:10.1016/j.ejca.2022.08.015	Mon, 12 Sep 2022 06:00:00 -0400
6	pubmed:36096041	Effect of glioma-derived immunoglobulin on biological function of glioma cells	Jiaoyun Lv Suhua Chen Xin Chen Jiawei Xie Ziyi He Tianrui Fan Kaiming Ma Kayisaier Abudurousuli Jun Yang Xiaoyan Qiu Hui Dai	CONCLUSION: Ig was expressed in glioma tissues and cell lines, and a high expression level predicted a poor prognosis of patients. Glioma-derived IgG promoted glioma cell proliferation and migration through the HGF/SF-Met or FAK/Src pathway.	pmid:36096041 doi:10.1016/j.ejca.2022.08.006	Mon, 12 Sep 2022 06:00:00 -0400
7	pubmed:36096071	A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer	Xiaomeng Jia Kainan Wang Lingzhi Xu Ning Li Zuowei Zhao Man Li	CONCLUSION: According to our meta-analysis of 22 trials in TNBC, BRCA1/2 mutation carriers were significantly more sensitive to PBC regimens, especially in neoadjuvant and advanced therapy.	pmid:36096071 doi:10.1016/j.breast.2022.08.012	Mon, 12 Sep 2022 06:00:00 -0400
8	pubmed:36096161	Discovery of semisynthetic celastrol derivatives exhibiting potent anti-ovarian cancer stem cell activity and STAT3 inhibition	Na Li Chaobo Li Juan Zhang Qian Jiang Zhaoxue Wang Shaozhen Nie Zhenzhen Gao Guangyao Li Hao Fang Shaoda Ren Xiaojing Li	The hallmark of ovarian cancer is its high mortality rate attributed to the existence of cancer stem cells (CSCs) subpopulations which result in therapy recurrence and metastasis. A series of C-29-substituted and/or different A/B ring of celastrol derivatives were synthesized and displayed potential inhibition against ovarian cancer cells SKOV3, A2780 and OVCAR3. Among them, compound 6c exhibited the most potent anti-proliferative activity and selectivity, gave superior anti-CSC effects through...	pmid:36096161 doi:10.1016/j.cbi.2022.110172	Mon, 12 Sep 2022 06:00:00 -0400
9	pubmed:36096189	Antiangiogenic AAV2 gene therapy with a truncated form of soluble VEGFR-2 reduces the growth of choroidal neovascularization in mice after intravitreal injection	Jooseppi Puranen Sanna Koponen Tiina Nieminen Iiris Kanerva Emmi Kokki Pyry Toivanen Arto Urtti Seppo Ylä-Herttuala Marika Ruponen	Pathological angiogenesis related to neovascularization in the eye is mediated through vascular endothelial growth factors (VEGFs) and their receptors. Ocular neovascular-related diseases are mainly treated with anti-VEGF agents. In this study we evaluated the efficacy and safety of novel gene therapy using adeno associated virus 2 vector expressing a truncated form of soluble VEGF receptor-2 fused to the Fc-part of human IgG1 (AAV2-sVEGFR-2-Fc) to inhibit ocular neovascularization in laser...	pmid:36096189 doi:10.1016/j.exer.2022.109237	Mon, 12 Sep 2022 06:00:00 -0400

	NCT Number	Title	Authors	Description	Identifier	Dates
10	pubmed:36096239	Integrating Epigenetics and Metabolomics to Advance Treatments for Pulmonary Arterial Hypertension	A Dushani C U Ranasinghe Margaret A Schwarz	Pulmonary arterial hypertension (PAH) is a devastating vascular disease with multiple etiologies.Emerging evidence supports a fundamental role for epigenetic machinery and metabolism in the initiation and progressionof PAH. Here, we summarize emerging epigenetic mechanisms that have been identified as contributors to PAH evolution, specifically, DNA methylation, histone modifications, and microRNAs. Furthermore, the interplay between epigenetics with metabolism is explored while new crosstalk...	pmid:36096239 doi:10.1016/j.bcp.2022.115245	Mon, 12 Sep 2022 06:00:00 -0400
11	pubmed:36096276	Vesicular stomatitis virus sensitizes immunologically cold tumors to checkpoint blockade by inducing pyroptosis	Jing Lin Fei Liu Fei Gao Yujia Chen Renling Wang Xinyue Wang Yue Li Qi Li Shihui Sun Zi Li Yungang Lan Huijun Lu Wei Guo Li Du Feng Gao Deguang Song Kui Zhao Jiyu Guan Wenqi He	CONCLUSIONS: Oncolytic VSV induces tumor cell pyroptosis by activating GSDME. GSDME is critical in recruiting cytotoxic T lymphocytes in the context of VSV therapy, which can switch immunologically 'cold' tumors into 'hot' and enhance immune checkpoint therapy efficacy.	pmid:36096276 doi:10.1016/j.bbadis.2022.166538	Mon, 12 Sep 2022 06:00:00 -0400
12	pubmed:36096336	Accurate treatment of small cell lung cancer: Current progress, new challenges and expectations	Chenyue Zhang Haiyong Wang	Small cell lung cancer (SCLC) is a deadly disease with poor prognosis. Fast growing speed, inclination to metastasis, enrichment in cancer stem cells altogether constitute its aggressive nature. In stark contrast to non-small cell lung cancer (NSCLC) that strides vigorously on the road to precision oncology, SCLC has been on the embryonic path to achieve effective personalized treatments. The survival of patients with SCLC have not been improved greatly, which could be possibly due to our...	pmid:36096336 doi:10.1016/j.bbcan.2022.188798	Mon, 12 Sep 2022 06:00:00 -0400
13	pubmed:36096355	Silencing SIRT5 induces the senescence of UCB-MSCs exposed to TNF- by reduction of fatty acid -oxidation and anti-oxidation	Young Hyun Jung Chang Woo Chae Han Seung Chang Gee Euhn Choi Hyun Jik Lee Ho Jae Han	Tumor necrosis factor- (TNF-) is an inflammatory cytokine involved in cell survival, apoptosis, and homeostasis. However, the regulatory effect of TNF- on mesenchymal stem cell (MSC) redox regulation remains unknown. The process of delaying the senescence of MSCs and maintaining antioxidation mechanism is important in transplantation therapy to treat inflammatory diseases that result from restricted immunomodulatory effects of senescent MSCs. Thus, we examined the role of TNF--mediated...	pmid:36096355 doi:10.1016/j.freeradbiomed.2022.09.002	Mon, 12 Sep 2022 06:00:00 -0400

	NCT Number	Title	Authors	Description	Identifier	Dates
14	pubmed:36096356	Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate experimental non-alcoholic steatohepatitis via Nrf2/NQO-1 pathway	Yaxing Kang Yiran Song Yuxin Luo Jia Song Chenyang Li Shuangshuang Yang Jinbo Guo Jun Yu Xiaolan Zhang	CONCLUSION: Nrf2/NQO-1 antioxidant signaling pathway may play a key role in the treatment of NASH by hUC-MSCs exosomes.	pmid:36096356 doi:10.1016/j.freeradbiomed.2022.08.037	Mon, 12 Sep 2022 06:00:00 -0400
15	pubmed:36096364	Local delivery of gambogic acid to improve anti-tumor immunity against oral squamous cell carcinoma	Xinmian Chen De-Run Chen Hongmei Liu Lei Yang Yutao Zhang Lin-Lin Bu Zhi-Jun Sun Lulu Cai	Oral squamous cell carcinoma (OSCC) accounts for nearly 90% of oral cavity malignancies. However, despite significant advances in the last four decades, little improvement has been achieved in the overall survival rates for OSCC patients. While gambogic acid (GA) is a potential candidate compound for treating a variety of malignancies, its anti-cancer impact on OSCC has yet to be completely investigated. The tumor immune microenvironment (TIME) has been proven to play a crucial role in the...	pmid:36096364 doi:10.1016/j.jconrel.2022.09.010	Mon, 12 Sep 2022 06:00:00 -0400
16	pubmed:36096366	Tumor immunotherapy boosted by R837 nanocrystals through combining chemotherapy and mild hyperthermia	Zhengjie Meng Xue Fang Bowen Fu Cheng Qian Zheng Yang Yunhao Bai Xinyue Tao Haixiao Huang Chenyu Ma Wenjun Miao Hao Ren Aiyun Wang Xueming Li	Melanoma is a malignant skin cancer that is prone to metastasis in the early stage and has a poor prognosis. Immunomodulatory therapy for melanoma has been a hot research topic in recent years. However, low immune cell infiltration and loss of tumor immunogenicity may occur in tumors, resulting in low response rates to immunotherapy. Thus, immunomodulatory therapy is usually used in combination with chemotherapy and radiotherapy. Development of combined therapeutic strategies with low systemic...	pmid:36096366 doi:10.1016/j.jconrel.2022.09.009	Mon, 12 Sep 2022 06:00:00 -0400
17	pubmed:36096368	ATP7B genotype and chronic liver disease treatment outcomes in Wilson disease: worse survival with loss of function variants	Jeremy S Nayagam Rebecca Jeyaraj Pierre Foskett Anil Dhawan Aftab Ala Deepak Joshi Adrian Bomford Richard J Thompson	CONCLUSIONS: Patients with WD and CLD phenotype on chelators, who have at least one LOF variant in ATP7B, have a worse prognosis during long-term follow up. This subgroup of patients requires close monitoring for signs of progressive liver disease. Sequencing of ATP7B may be used in the diagnosis of WD, in addition it may provide useful prognostic information for patients with hepatic WD.	pmid:36096368 doi:10.1016/j.cgh.2022.08.041	Mon, 12 Sep 2022 06:00:00 -0400
18	pubmed:36096417	The Immunobiogram, a novel in vitro diagnostic test to measure the pharmacodynamic response to immunosuppressive therapy in kidney transplant patients	Julio Pascual Carlos Jiménez Magdalena Krajewska Daniel Seron Camille N Kotton Jose Portolés Oliver Witzke Soren S Sorensen Amado Andrés Marta Crespo Estela Paz-Artal Teresa Díez Alvaro Ortega Isabel Portero	CONCLUSIONS: Our results highlight the potential of Immunobiogram as a tool to test the pharmacodynamic response to individual immunosuppressive drugs.	pmid:36096417 doi:10.1016/j.trim.2022.101711	Mon, 12 Sep 2022 06:00:00 -0400

	NCT Number	Title	Authors	Description	Identifier	Dates
19	pubmed:36096420	Nucleic acid therapy in pediatric cancer	Yongshu Li Bihui Huang Zhichao Xue Yunhua Gao Zhenjian Zhuo	The overall survival, progress free survival, and life quality of cancer patients have improved due to the advance in minimally invasive surgery, precision radiotherapy, and various combined chemotherapy in the last decade. Furthermore, the discovery of new types of therapeutics, such as immune checkpoint inhibitors and immune cell therapies have facilitated both patients and doctors to fight with cancers. Moreover, in the context of the development in biocompatible and cell type targeting...	pmid:36096420 doi:10.1016/j.phrs.2022.106441	Mon, 12 Sep 2022 06:00:00 -0400
20	pubmed:36096429	Use of biomarkers to individualize antimicrobial therapy duration: a narrative review	Jake Scott Stan Deresinski	BACKGROUND: Reducing the overuse of antimicrobials is imperative for the sake of minimizing antimicrobial-associated adverse effects, optimizing resource utilization, and curtailing the rise in multidrug-resistant organisms. Biomarkers reflect host responses to infection and may assist with minimizing unnecessary antimicrobial usage.	pmid:36096429 doi:10.1016/j.cmi.2022.08.026	Mon, 12 Sep 2022 06:00:00 -0400
21	pubmed:36096442	Efficacy of Brigatinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Who Progressed on Alectinib or Ceritinib: ALTA-2 Study	Sai-Hong Ignatius Ou Makoto Nishio Myung-Ju Ahn Tony Mok Fabrice Barlesi Caicun Zhou Enriqueta Felip Filippo de Marinis Sang-We Kim Maurice Pérol Geoffrey Liu Maria Rita Migliorino Dong-Wan Kim Silvia Novello Alessandra Bearz Pilar Garrido Julien Mazieres Alessandro Morabito Huamao M Lin Hui Yang Huifeng Niu Pingkuan Zhang Edward S Kim	CONCLUSION: In ALTA-2, brigatinib demonstrated limited activity in patients with ALK+ NSCLC post-ceritinib or post-alectinib therapy. Median PFS was longer with brigatinib in patients without baseline detectable plasma ALK fusion.	pmid:36096442 doi:10.1016/j.jtho.2022.08.018	Mon, 12 Sep 2022 06:00:00 -0400
22	pubmed:36096457	Characterisation of broad-spectrum phiKZ like jumbo phage and its utilisation in controlling multidrug-resistant Pseudomonas aeruginosa isolates	Praveen Rai Shruthi Seetharam Shetty Sujana Prabell Akshatha Kuntar Deepak Pinto Ballamoole Krishna Kumar Divyashree Mithoor Juliet Roshini Mohan Raj Ramya Harsha Vijay Kumar Deekshit Indrani Karunasagar Iddya Karunasagar	The emergence of highly virulent multidrug-resistant P. aeruginosa has become increasingly evident among hospital-acquired infections and has raised the need for alternative therapies. Phage therapy can be one such alternative to antibiotic therapy to combat multidrug-resistant pathogenic bacteria, but this requires the availability of phages with a broad host range. In this study, isolation and molecular characterisation of P. aeruginosa specific phages were carried out. A total of 17 phages...	pmid:36096457 doi:10.1016/j.micpath.2022.105767	Mon, 12 Sep 2022 06:00:00 -0400

	NCT Number	Title	Authors	Description	Identifier	Dates
23	pubmed:36096460	Molecular pathways in periampullary cancer: An overview	None Apurva Real Sumayya Abdul Sattar Asgar Ali None Nimisha Abhay Kumar Sharma None ArunKumar Seneha Santoshi Sundeep Singh Saluja	Molecular alterations in oncogenes and tumor suppressors in various signaling pathways are basis for personalized therapy in cancer. Periampullary carcinoma behaves differently from pancreatic carcinoma both in prognosis and outcome, therefore it needs special attention. Pancreatic cancer have higher incidence of nodal spread and perineural &lymphovascular invasion suggesting it biologically more aggressive tumor compared to periampullary cancer. Since PAC tumors consist of heterogenous tissue...	pmid:36096460 doi:10.1016/j.cellsig.2022.110461	Mon, 12 Sep 2022 06:00:00 -0400
24	pubmed:36096509	A case of multiple primary lung adenocarcinoma with a CD74-NRG1 fusion protein and HER2 mutation benefit from combined target therapy	Kai Chen Wen Li Xiaoming Xi Jia Zhong	Neuregulin 1 (NRG1) gene fusion is a rare oncogenic driver gene in multiple tumor types, leading to the activation of the epidermal growth factor receptor (ErbB)-mediated pathway. Therefore, afatinib, a pan-ErbB family inhibitor, may be a therapeutic candidate for NRG1 fusion-driven tumors. In this case, we report a multiple primary lung adenocarcinoma patient harboring the CD74-NRG1 fusion, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (ERBB2) mutation...	pmid:36096509 doi:10.1111/1759-7714.14636	Mon, 12 Sep 2022 06:00:00 -0400
25	pubmed:36096527	Label-free metabolic imaging for sensitive and robust monitoring of anti-CD47 immunotherapy response in triple-negative breast cancer	Minfeng Yang Arpan Mahanty Chunjing Jin Alex Ngai Nick Wong Jung Sun Yoo	CONCLUSIONS: Collectively, this study showcases the potential of the LMII technique as a powerful tool to visualize dynamic changes of heterogeneous cell metabolism of cancer cells and immune infiltrates in response to immunotherapy thus providing sensitive and complete monitoring. Leveraged on ability to differentiate cancer cells and immunosuppressive macrophages, the presented imaging approach provides particularly useful imaging biomarkers for emerged innate immune checkpoint inhibitors such...	pmid:36096527 doi:10.1136/jitc-2022-005199	Mon, 12 Sep 2022 06:00:00 -0400
26	pubmed:36096530	Automated, scaled, transposon-based production of CAR T cells	Dominik Lock Razieh Monjezi Caroline Brandes Stephan Bates Simon Lennartz Karin Teppert Leon Gehrke Rafailla Karasakalidou-Seidt Teodora Lukic Marco Schmeer Martin Schleef Niels Werchau Matthias Eyrich Mario Assenmacher Andrew Kaiser Sabrina Prommersberger Thomas Schaser Michael Hudecek	CONCLUSIONS: We report on the first automated transposon-based manufacturing process for CAR T cells that is ready for formal validation and use in clinical manufacturing campaigns. This process and platform have the potential to facilitate access of patients to CAR T cell therapy and to accelerate scaled, multiplexed manufacturing both in the academic and industry setting.	pmid:36096530 doi:10.1136/jitc-2022-005189	Mon, 12 Sep 2022 06:00:00 -0400

	NCT Number	Title	Authors	Description	Identifier	Dates
27	pubmed:36096531	Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites	Jordan W Conway Robert V Rawson Serigne Lo Tasnia Ahmed Ismael A Vergara Tuba N Gide Grace Heloise Attrill Matteo S Carlino Robyn P M Saw John F Thompson Andrew J Spillane Kerwin F Shannon Brindha Shivalingam Alexander Maxwell Menzies James S Wilmott Georgina V Long Richard A Scolyer Ines Pires da Silva	CONCLUSIONS: Liver and brain melanoma metastases have a significantly reduced immune infiltrate than lung, subcut and LN metastases, which may account for poorer prognosis and reduced immunotherapy response rates in patients with liver or brain metastases. Increased TIM-3 expression in liver metastases suggests TIM-3 inhibitor therapy as a potential therapeutic opportunity to improve patient outcomes.	pmid:36096531 doi:10.1136/jitc-2022-004884	Mon, 12 Sep 2022 06:00:00 -0400
28	pubmed:36096534	COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis	Rikke Boedker Holmstroem Ole Haagen Nielsen Søren Jacobsen Lene Buhl Riis Susann Theile Jacob Tveiten Bjerrum Peter Vilmann Julia Sidenius Johansen Mogens Karsbøl Boisen Rikke Helene Løvendahl Eefsen Inge Marie Svane Dorte Lisbet Nielsen Inna Markovna Chen	CONCLUSIONS: Tocilizumab showed promising clinical efficacy and a manageable safety profile in the treatment of ICI-induced colitis and arthritis. Our findings support the feasibility of randomized trials of immune-related adverse events.	pmid:36096534 doi:10.1136/jitc-2022-005111	Mon, 12 Sep 2022 06:00:00 -0400
29	pubmed:36096545	Trial by "Firsts": Clinical Trial Design and Regulatory Considerations in the Development and Approval of the First AAV Gene Therapy Product in the United States	Kathleen Z Reape Katherine A High	Given the therapeutic potential of supplying a normal copy of a mutant gene to the correct target tissue, gene therapy holds extraordinary promise for the treatment of genetic disease. Like other novel classes of therapeutics however, gene therapies must overcome a range of clinical, regulatory, and manufacturing hurdles to reach regulatory approval. This paper reviews key aspects of clinical trial design, development, and evaluation of a novel primary end point, and regulatory interactions that...	pmid:36096545 doi:10.1101/cshperspect.a041312	Mon, 12 Sep 2022 06:00:00 -0400
30	pubmed:36096566	What Surgeons Need to Know About Gene Therapy for Cancer	Shanmugappiriya Sivarajah Kevin Emerick Howard L Kaufman	The broad field of gene therapy offers numerous innovative approaches for cancer treatment. An understanding of the different modalities including gene replacement therapy, cancer vaccines, oncolytic viruses, cellular therapy, and gene editing is essential for managing patients with neoplastic disease. As in other areas of oncology, the surgeon plays a pivotal role in the diagnosis and treatment of the disease. This review focuses on what the clinical surgeon needs to know to optimize the...	pmid:36096566 doi:10.1016/j.yasu.2022.02.006	Mon, 12 Sep 2022 06:00:00 -0400

	NCT Number	Title	Authors	Description	Identifier	Dates
31	pubmed:36096567	Is There a Place for Hyperbaric Oxygen Therapy?	Kinjal N Sethuraman Ryan Smolin Sharon Henry	Hyperbaric oxygen therapy (HBOT) involves treating patients by providing 100% oxygen through inhalation while inside a treatment pressurized chamber. The oxygen acts as a drug and the hyperbaric chamber as the dosing device. The effect of hyperbaric hyperoxia is dose dependent and, therefore, treatment depth and duration are important when considering its use. HBOT can either be the primary method of treatment or used adjunctively to medications or surgical techniques. The underpinning...	pmid:36096567 doi:10.1016/j.yasu.2022.02.011	Mon, 12 Sep 2022 06:00:00 -0400
32	pubmed:36096774	A case of novel DYT6 dystonia variant with serious complications after deep brain stimulation therapy: a case report	M Grofik M Cibulka J Olekšáková M Turanová Koprušáková T Galanda J Necpál P Jungová E Kura J Winkelmann M Zech R Jech	CONCLUSIONS: DBS in the case of DYT6 dystonia is a challenge to thoroughly consider possible therapeutic benefits and potential risks associated with surgery. Genetic heterogeneity of the disease may also play an important role in predicting the development of the clinical phenotype as well as the effect of treatment including DBS. Therefore, it is beneficial to analyze the genetic and clinical relationships of DYT6 dystonia.	pmid:36096774 doi:10.1186/s12883-022-02871-3	Mon, 12 Sep 2022 06:00:00 -0400
33	pubmed:36096847	Liquid biopsy: current technology and clinical applications	Mina Nikanjam Shumei Kato Razelle Kurzrock	Liquid biopsies are increasingly used for cancer molecular profiling that enables a precision oncology approach. Circulating extracellular nucleic acids (cell-free DNA; cfDNA), circulating tumor DNA (ctDNA), and circulating tumor cells (CTCs) can be isolated from the blood and other body fluids. This review will focus on current technologies and clinical applications for liquid biopsies. ctDNA/cfDNA has been isolated and analyzed using many techniques, e.g., droplet digital polymerase chain...	pmid:36096847 doi:10.1186/s13045-022-01351-y	Mon, 12 Sep 2022 06:00:00 -0400
34	pubmed:36096856	Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies	Hailong Tian Tingting Zhang Siyuan Qin Zhao Huang Li Zhou Jiayan Shi Edouard C Nice Na Xie Canhua Huang Zhisen Shen	Poor targeting of therapeutics leading to severe adverse effects on normal tissues is considered one of the obstacles in cancer therapy. To help overcome this, nanoscale drug delivery systems have provided an alternative avenue for improving the therapeutic potential of various agents and bioactive molecules through the enhanced permeability and retention (EPR) effect. Nanosystems with cancer-targeted ligands can achieve effective delivery to the tumor cells utilizing cell surface-specific...	pmid:36096856 doi:10.1186/s13045-022-01320-5	Mon, 12 Sep 2022 06:00:00 -0400
35	pubmed:36096861	E3 ubiquitin ligase Trim33 ubiquitylates Annexin A2 to promote NF-B induced skin inflammation in psoriasis	Jie Zhang Jiuling Zhu Xiaowen Chen Haibin Xia Luting Yang	CONCLUSIONS: Our study highlights the upregulation of Trim33 in psoriatic epidermis and its pivotal role in promoting the inflammation of keratinocytes by Anxa2/NF-B pathway. Our findings imply that Trim33 might be further explored as potential target for psoriasis treatment.	pmid:36096861 doi:10.1016/j.jdermsci.2022.09.002	Mon, 12 Sep 2022 06:00:00 -0400

	NCT Number	Title	Authors	Description	Identifier	Dates
36	pubmed:36096933	Therapy with voretigene neparvovec. How to measure success?	Krunoslav Stingl Melanie Kempf Ronja Jung Friederike Kortüm Giulia Righetti Milda Reith Spyridon Dimopoulos Saskia Ott Susanne Kohl Katarina Stingl	Retinal gene supplementation therapy such as the first approved one, voretigene neparvovec, delivers a functioning copy of the missing gene enabling the protein transcription in retinal cells and restore visual functions. After gene supplementation for the genetic defect, a complex network of functional regeneration is the consequence, whereas the extent is very individualized. Diagnostic and functional testings that have been used routinely by ophthalmologists so far to define the correct...	pmid:36096933 doi:10.1016/j.preteyeres.2022.101115	Mon, 12 Sep 2022 06:00:00 -0400
37	pubmed:36096985	Direct conversion of human umbilical cord mesenchymal stem cells into retinal pigment epithelial cells for treatment of retinal degeneration	Xiaoman Zhu Zhiyang Chen Li Wang Qingjian Ou Zhong Feng Honglei Xiao Qi Shen Yingao Li Caixia Jin Jing-Ying Xu Furong Gao Juan Wang Jingfa Zhang Jieping Zhang Zhiguo Xu Guo-Tong Xu Lixia Lu Haibin Tian	Age-related macular degeneration (AMD) is a major vision-threatening disease. Although mesenchymal stem cells (MSCs) exhibit beneficial neural protective effects, their limited differentiation capacity in vivo attenuates their therapeutic function. Therefore, the differentiation of MSCs into retinal pigment epithelial (RPE) cells in vitro and their subsequent transplantation into the subretinal space is expected to improve the outcome of cell therapy. Here, we transdifferentiated human umbilical...	pmid:36096985 doi:10.1038/s41419-022-05199-5	Mon, 12 Sep 2022 06:00:00 -0400
38	pubmed:36096991	Clinical features of type 1 and 2 refractory celiac disease: Results from a large cohort over a decade	Luca Elli Pietro Soru Leda Roncoroni Francesca Gaia Rossi Valeria Ferla Luca Baldini Nicoletta Nandi Lucia Scaramella Alice Scricciolo Alessandro Rimondi Nicola Fusco Giorgio Alberto Croci Umberto Gianelli Lilla Cro Marzia Barbieri Vincenza Lombardo Andrea Costantino Valentina Vaira Stefano Ferrero Gian Eugenio Tontini Giulio Barigelletti Sabrina Fabiano Luisa Doneda Maurizio Vecchi	CONCLUSIONS: Clinical severity, response to therapy, and mortality differ between RCeD-I and RCeD-II. Atrophy extension, evaluated at capsule endoscopy, was associated with disease severity and mortality.	pmid:36096991 doi:10.1016/j.dld.2022.08.022	Mon, 12 Sep 2022 06:00:00 -0400

	NCT Number	Title	Authors	Description	Identifier	Dates
39	pubmed:36096995	Sickle cell disease in the new era: Advances in drug treatment	Margaret T Lee Ugochi O Ogu	Sickle cell disease is an inherited blood disorder afflicting an estimated 100,000 individuals in the United States and over 20 million people worldwide. The disease is heralded as the first molecular disease. However, despite its genetic simplicity, the pathophysiologic processes leading to its clinical sequelae are complex, heterogeneous and interrelated, making drug development to treat the disease challenging. For over two decades only one drug, hydroxyurea, had been used as...	pmid:36096995 doi:10.1016/j.transci.2022.103555	Mon, 12 Sep 2022 06:00:00 -0400
40	pubmed:36096997	TAZ/YAP fusion proteins: mechanistic insights and therapeutic opportunities	Keith Garcia Anne-Claude Gingras Kieran F Harvey Munir R Tanas	The Hippo pathway is dysregulated in many different cancers, but point mutations in the pathway are rare. Transcriptional co-activator with PDZ-binding motif (TAZ) and Yes-associated protein (YAP) fusion proteins have emerged in almost all major cancer types and represent the most common genetic mechanism by which the two transcriptional co-activators are activated. Given that the N termini of TAZ or YAP are fused to the C terminus of another transcriptional regulator, the resultant fusion...	pmid:36096997 doi:10.1016/j.trecan.2022.08.002	Mon, 12 Sep 2022 06:00:00 -0400
41	pubmed:36097040	Comparable survival outcomes with haploidentical stem cell transplantation and unrelated bone marrow transplantation	Yoshiko Atsuta Junichi Sugita Hirohisa Nakamae Yumiko Maruyama Ken Ishiyama Souichi Shiratori Takahiro Fukuda Mio Kurata Naoki Shingai Yukiyasu Ozawa Masayoshi Masuko Koji Nagafuji Satoru Takada Shinichi Kako Yoshinobu Kanda Junya Kanda Tatsuo Ichinohe Takanori Teshima	We retrospectively compared outcomes of unrelated donor bone marrow transplant (UBMT) and HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide (PTCy-haploPBSCT) using the Japanese registry data. Recipients of first HCT for acute leukemia and myelodysplastic syndromes between 2012 and 2015 were included. The analyzed subjects comprised UBMT recipients with 8/8 matched HLA alleles (n = 1470), 7/8 matched alleles (n = 859), 6/8 matched alleles (n =...	pmid:36097040 doi:10.1038/s41409-022-01822-3	Mon, 12 Sep 2022 06:00:00 -0400
42	pubmed:36097207	Emerging concepts of type I interferons in SLE pathogenesis and therapy	Antonios Psarras Miriam Wittmann Edward M Vital	Type I interferons have been suspected for decades to have a crucial role in the pathogenesis of systemic lupus erythematosus (SLE). Evidence has now overturned several long-held assumptions about how type I interferons are regulated and cause pathological conditions, providing a new view of SLE pathogenesis that resolves longstanding clinical dilemmas. This evidence includes data on interferons in relation to genetic predisposition and epigenetic regulation. Importantly, data are now available...	pmid:36097207 doi:10.1038/s41584-022-00826-z	Tue, 13 Sep 2022 06:00:00 -0400

	NCT Number	Title	Authors	Description	Identifier	Dates
43	pubmed:36097221	Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma	Nicholas J Haradhvala Mark B Leick Katie Maurer Satyen H Gohil Rebecca C Larson Ning Yao Kathleen M E Gallagher Katelin Katsis Matthew J Frigault Jackson Southard Shuqiang Li Michael C Kann Harrison Silva Max Jan Kahn Rhrissorrakrai Filippo Utro Chaya Levovitz Raquel A Jacobs Kara Slowik Brian P Danysh Kenneth J Livak Laxmi Parida Judith Ferry Caron Jacobson Catherine J Wu Gad Getz Marcela V Maus	Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic malignancies. Approximately half of patients with refractory large B cell lymphomas achieve durable responses from CD19-targeting CAR-T treatment; however, failure mechanisms are identified in only a fraction of cases. To gain new insights into the basis of clinical response, we performed single-cell transcriptome sequencing of 105 pretreatment and post-treatment peripheral blood mononuclear cell...	pmid:36097221 doi:10.1038/s41591-022-01959-0	Tue, 13 Sep 2022 06:00:00 -0400
44	pubmed:36097223	Post-infusion CAR T_{Reg} cells identify patients resistant to CD19-CAR therapy	Zinaida Good Jay Y Spiegel Bita Sahaf Meena B Malipatlolla Zach J Ehlinger Sreevidya Kurra Moksha H Desai Warren D Reynolds Anita Wong Lin Panayiotis Vandris Fang Wu Snehit Prabhu Mark P Hamilton John S Tamaresis Paul J Hanson Shabnum Patel Steven A Feldman Matthew J Frank John H Baird Lori Muffly Gursharan K Claire Juliana Craig Katherine A Kong Dhananjay Wagh John Coller Sean C Bendall Robert J Tibshirani Sylvia K Plevritis David B Miklos Crystal L Mackall	Approximately 60% of patients with large B cell lymphoma treated with chimeric antigen receptor (CAR) T cell therapies targeting CD19 experience disease progression, and neurotoxicity remains a challenge. Biomarkers associated with resistance and toxicity are limited. In this study, single-cell proteomic profiling of circulating CAR T cells in 32 patients treated with CD19-CAR identified that CD4^(+)Helios^(+) CAR T cells on day 7 after infusion are associated with progressive disease and less...	pmid:36097223 doi:10.1038/s41591-022-01960-7	Tue, 13 Sep 2022 06:00:00 -0400
45	pubmed:36097225	A combined stem-cell-gene therapy strategy for ALS	Hideyuki Okano	No abstract	pmid:36097225 doi:10.1038/s41591-022-01983-0	Tue, 13 Sep 2022 06:00:00 -0400

	NCT Number	Title	Authors	Description	Identifier	Dates
46	pubmed:36097267	Crosstalk of Synapsin1 palmitoylation and phosphorylation controls the dynamicity of synaptic vesicles in neurons	Peipei Yan Huicong Liu Tao Zhou Pu Sun Yilin Wang Xibin Wang Lin Zhang Tian Wang Jing Dong Jiangli Zhu Luxian Lv Wenqiang Li Shiqian Qi Yinming Liang Eryan Kong	The dynamics of synaptic vesicles (SVs) within presynaptic domains are tightly controlled by synapsin1 phosphorylation; however, the mechanism underlying the anchoring of synapsin1 with F-actin or SVs is not yet fully understood. Here, we found that Syn1 is modified with protein palmitoylation, and examining the roles of Syn1 palmitoylation in neurons led us to uncover that Syn1 palmitoylation is negatively regulated by its phosphorylation; together, they manipulate the clustering and...	pmid:36097267 doi:10.1038/s41419-022-05235-4	Tue, 13 Sep 2022 06:00:00 -0400
47	pubmed:36097283	Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial	Anna Eichinger Ulrike Poetschger Evgenia Glogova Peter Bader Oliver Basu Rita Beier Birgit Burkhardt Carl-Friedrich Classen Alexander Claviez Selim Corbacioglu Hedwig E Deubzer Johann Greil Bernd Gruhn Tayfun Güngör Kinan Kafa Jörn-Sven Kühl Peter Lang Bjoern Soenke Lange Roland Meisel Ingo Müller Martin G Sauer Paul-Gerhardt Schlegel Ansgar Schulz Daniel Stachel Brigitte Strahm Angela Wawer Christina Peters Michael H Albert	Total body irradiation (TBI)-based conditioning is associated with superior leukemia-free survival in children with ALL undergoing HSCT. However, the risk for subsequent malignant neoplasms (SMN) remains a significant concern. We analyzed 705 pediatric patients enrolled in the prospective ALL-SCT-BFM-2003 trial and its subsequent registry. Patients >2 years received conditioning with TBI 12 Gy/etoposide (n = 558) and children 2 years of age or with contraindications for TBI received...	pmid:36097283 doi:10.1038/s41375-022-01693-z	Tue, 13 Sep 2022 06:00:00 -0400
48	pubmed:36097299	S-1 + Cisplatin with Concurrent Radiotherapy Followed by Surgery for Stage IIIA (N2) Lung Squamous Cell Carcinoma: Results of a Phase II Trial	Kazuya Takamochi Masahiro Tsuboi Morihito Okada Seiji Niho Satoshi Ishikura Shunsuke Oyamada Takuhiro Yamaguchi Kenji Suzuki Advanced Clinical Trial Chest Surgery Group (ACTG)	CONCLUSIONS: Induction therapy using S-1 + cisplatin with concurrent TRT followed by surgery is a feasible and promising treatment approach for stage IIIA (N2) LSCC.	pmid:36097299 doi:10.1245/s10434-022-12490-4	Tue, 13 Sep 2022 06:00:00 -0400

	NCT Number	Title	Authors	Description	Identifier	Dates
49	pubmed:36097336	The Mayo Clinic Florida microdosimetric kinetic model of clonogenic survival: formalism and first benchmark against*in vitro* and*in silico*data	Alessio Parisi Chris J Beltran Keith M Furutani	Objective. To develop a new model (Mayo Clinic Florida microdosimetric kinetic model, MCF MKM) capable of accurately describing thein vitroclonogenic survival at low and high linear energy transfer (LET) using single-event microdosimetric spectra in a single target.Methodology. The MCF MKM is based on the 'post-processing average' implementation of the non-Poisson microdosimetric kinetic model and includes a novel expression to compute the particle-specific quadratic-dependence of the cell...	pmid:36097336 doi:10.1088/1361-6560/ac7375	Tue, 13 Sep 2022 06:00:00 -0400
50	pubmed:36097378	Efficacy and safety of topical brimonidine in dermatology: A review article	Nasrin Saki Maliheh Amani Nazanin Zeinali Nezhad Amirhossein Shahpar Mohadeseh Shafiei Seyed Ali Hosseini Najmeh Ahramiyanpour	CONCLUSION: Based on our findings, brimonidine is a beneficial drug that can be used in various dermatologic disorders with negligible side effects. This article is protected by copyright. All rights reserved.	pmid:36097378 doi:10.1111/dth.15819	Tue, 13 Sep 2022 06:00:00 -0400
51	pubmed:36097397	Skin Infections Due to Panton-Valentine Leukocidin-Producing S. Aureus	Rasmus Leistner Leif G Hanitsch Renate Krüger Andreas K Lindner Miriam S Stegemann Dennis Nurjadi	CONCLUSION: PVL-SA skin infections are easily distinguished from other skin diseases with targeted history-taking and diagnostic evaluation.	pmid:36097397 doi:10.3238/arztebl.m2022.0308	Tue, 13 Sep 2022 06:00:00 -0400
52	pubmed:36097543	Single-cell transcriptome landscape and antigen receptor dynamic during SARS-CoV-2 vaccination	Xiaojian Cao Xiaohua Chen Yaqi Zhu Xiaojuan Gou Keyi Yan Bing Yang Dong Men Lei Liu Yong-An Zhang Gang Cao	Vaccination by inactivated vaccine is an effective strategy to prevent the COVID-19 pandemic. However, the detailed molecular immune response at single-cell level is poorly understood. In this study, we systematically delineated the landscape of the pre- and post-vaccination single-cell transcriptome, TCR (T cell antigen receptor) and BCR (B cell antigen receptor) expression profile of vaccinated candidates. The bulk TCR sequencing analysis of COVID-19 patients was also performed. Enrichment of...	pmid:36097543 pmc:PMC9454148 doi:10.1016/j.gendis.2022.08.020	Tue, 13 Sep 2022 06:00:00 -0400
53	pubmed:36097598	*In vivo* real-time red blood cell migration and microcirculation flow synergy imaging-surveyed thrombolytic therapy with iron-oxide complexes	Fei Ye Bei Zhang Lige Qiu Yunrui Zhang Yang Zhang Jian Zhang Qingliang Zhao Ligong Lu Zhenlin Zhang	Nanotherapeutics as a nascent method has attracted widely interest on the treatment of thrombosis. However, due to the limited temporal and spatial resolution of conventional imaging modalities, the dynamic visualization the thrombogenesis and evaluation of the effect of thrombolytic drugs are facing severely difficulties in vivo. In addition, the development of high targeting, short circulation time, and small size thrombolysis nanotherapeutics agents requires further research. Herein, we...	pmid:36097598 pmc:PMC9463387 doi:10.1016/j.mtbio.2022.100408	Tue, 13 Sep 2022 06:00:00 -0400
54	pubmed:36097605	FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation	Amanda Blackmon Ibrahim Aldoss Brian J Ball	Mutations in the FLT3 gene are associated with poor prognosis in patients with AML, even after consolidation with allogeneic hematopoietic cell transplantation (alloHCT) in first remission. Treatment failure in FLT3-mutated AML is largely driven by excessive risk of relapse compared to other genetic subtypes, including in patients post-alloHCT. As a result, there is substantial interest in studying posttransplant maintenance therapy in FLT3-mutated AML as an approach to optimize disease control...	pmid:36097605 pmc:PMC9464008 doi:10.2147/BLCTT.S281252	Tue, 13 Sep 2022 06:00:00 -0400

	NCT Number	Title	Authors	Description	Identifier	Dates
55	pubmed:36097617	Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters	Noortje van Gils Han J M P Verhagen Michaël Broux Tania Martiáñez Fedor Denkers Eline Vermue Arjo Rutten Tamás Csikós Sofie Demeyer Meryem Çil Marjon Al Jan Cools Jeroen J W M Janssen Gert J Ossenkoppele Renee X Menezes Linda Smit	Although chemotherapy induces complete remission in the majority of acute myeloid leukemia (AML) patients, many face a relapse. This relapse is caused by survival of chemotherapy-resistant leukemia (stem) cells (measurable residual disease; MRD). Here, we demonstrate that the anthracycline doxorubicin epigenetically reprograms leukemia cells by inducing histone 3 lysine 27 (H3K27) and H3K4 tri-methylation. Within a doxorubicin-sensitive leukemia cell population, we identified a subpopulation of...	pmid:36097617 pmc:PMC9463578 doi:10.1016/j.isci.2022.105013	Tue, 13 Sep 2022 06:00:00 -0400
56	pubmed:36097620	Metastatic same-site squamous cell carcinoma arising during vismodegib therapy for basal cell carcinoma	Raymond Zhao Bo Wang Lori Lowe Andrzej Dlugosz Christopher K Bichakjian	No abstract	pmid:36097620 pmc:PMC9463540 doi:10.1016/j.jdcr.2022.07.032	Tue, 13 Sep 2022 06:00:00 -0400
57	pubmed:36097632	Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma	Syeda Saba Kareem Neena Viswanathan Solmaz Sahebjam Nam D Tran Tyra Gatewood Katherine Tobon Rachid Baz Yolanda Piña Kenneth H Shain Sepideh Mokhtari	Leukoencephalopathy in the setting of multiple myeloma (MM) is a rare demyelinating condition, with few reported cases in literature. Daratumumab is a CD38 targeted monoclonal antibody that has been widely used for the management of MM. In the absence of central nervous system (CNS) disease, many medication-induced leukoencephalopathy cases reported with MM, including daratumumab-induced, are associated with progressive multifocal leukoencephalopathy (PML) and John Cunningham (JC) virus....	pmid:36097632 pmc:PMC9464026 doi:10.2147/OTT.S365657	Tue, 13 Sep 2022 06:00:00 -0400
58	pubmed:36097678	Comparative Study of Nano-liposome and Nano-niosome for Delivery of Achillea Millefolium Essential Oils: Development, Optimization, Characterization and Their Cytotoxicity Effects on Cancer Cell Line and Antibacterial Activity	Hamideh Emtiazi Ali Salari Sharif Mahdie Hemati BiBi Fatemeh Haghiralsadat Abbas Pardakhti	Nanoencapsulation of essential oils (EOs) in drug delivery systems leads to their capability of improving their solubility, stability, and bioavailability of them. The aim of this study was preparation, optimization, and characterization of nano-liposomes/nano-niosomes containing Achillea millefolium essential oils (A. millefolium EOs) and comparison of their properties. In the experimental study, characteristics of nanoparticles including size, zeta potential, Fourier Transform Infrared...	pmid:36097678 doi:10.1002/cbdv.202200397	Tue, 13 Sep 2022 06:00:00 -0400
59	pubmed:36097681	Designing coordination polymers as multi-drug-self-delivery systems for tuberculosis and cancer therapy: *in vitro* viability and *in vivo* toxicity assessment	Protap Biswas Hemanta Kumar Datta Parthasarathi Dastidar	A proof of concept for designing multi-drug-delivery systems suitable for self-drug-delivery is disclosed. Simple coordination chemistry was employed to anchor two kinds of drugs namely isoniazid (IZ - anti-tuberculosis), various non-steroidal-anti-inflammatory-drugs (NSAIDs) namely ibuprofen-IBU, fenoprofen-FEN, naproxen-NAP, diclofenac-DIC and mefenamic acid-MEF and Zn(NO(3))(2) to synthesize a series of 1D coordination polymers namely IZIBU, IZFEN, IZNAP, IZDIC and IZMEF which were...	pmid:36097681 doi:10.1039/d2bm00752e	Tue, 13 Sep 2022 06:00:00 -0400

	NCT Number	Title	Authors	Description	Identifier	Dates
60	pubmed:36097701	Characterization of SHARPIN knockout Syrian hamsters developed using CRISPR/Cas9 system	Jinxin Miao Tianfeng Lan Haoran Guo Jianyao Wang Guangtao Zhang Zheng Wang Panpan Yang Haoze Li Chunyang Zhang Yaohe Wang Xiu-Min Li Mingsan Miao	CONCLUSIONS: A novel SHARPIN KO hamster was successfully established using the CRISPR/Cas9 system. Abnormal development of secondary lymphoid organs and eosinophil infiltration in multiple organs reveal its potential in delineating SHARPIN function and chronic inflammation.	pmid:36097701 doi:10.1002/ame2.12265	Tue, 13 Sep 2022 06:00:00 -0400
61	pubmed:36097712	Genetic diversity of the human immunodeficiency virus (HIV-1) in the Kaliningrad region	A N Shchemelev A V Semenov Yu V Ostankova E V Naidenova E B Zueva D E Valutite M A Churina P A Virolainen A A Totolian	CONCLUSION: The observed diversity of subtypes and recombinant forms of the virus implies that the new recombinants are actively emerging in the studied region, both between existing recombinant forms and "pure" subtypes, as well as between "pure" subtypes.	pmid:36097712 doi:10.36233/0507-4088-119	Tue, 13 Sep 2022 06:00:00 -0400
62	pubmed:36097737	Intraovarian platelet-rich plasma administration could improve blastocyst euploidy rates in women undergoing in vitro fertilization	Zaher Merhi Serin Seckin Marco Mouanness	CONCLUSION: This novel study is the first to present an improvement in the embryo euploidy rate following intraovarian PRP application in infertile women with prior failed IVF cycles. The growth factors present in PRP may exhibit a local paracrine effect that could improve meiotic aberrations in human oocytes and thus improve euploidy rates. Whether PRP improves live birth rates and lowers miscarriage rates remains to be determined in large trials.	pmid:36097737 doi:10.5653/cerm.2021.05057	Tue, 13 Sep 2022 06:00:00 -0400
63	pubmed:36097751	The effect of photodynamic therapy using Radachlorin on biofilm-forming multidrug-resistant bacteria	Choong-Won Seo Young-Kwon Kim Jeong-Lib An Jong-Sook Kim Pil-Seung Kwon Young-Bin Yu	CONCLUSION: PDT involving a combination of LED and Radachlorin significantly eliminated the biofilm of multidrug-resistant A. baumannii. Observations made using electron microscopy showed that PDT combining LED and Radachlorin was effective. Additional studies on the effective elimination of biofilms containing multidrug-resistant bacteria are necessary, and we hope that a treatment method superior to sterilization with antibiotics will be developed in the future.	pmid:36097751 doi:10.24171/j.phrp.2022.0150	Tue, 13 Sep 2022 06:00:00 -0400
64	pubmed:36097758	Identification of broadly applicable AAV vectors by systematic comparison of commonly used capsid variants in vitro	Jonas Weinmann Julia Söllner Sarah Abele Gudrun Zimmermann Kai Zuckschwerdt Christine Mayer Jenny Danner-Liskus Alexander Peltzer Michael Schuler Thorsten Lamla Benjamin Strobel	Adeno-associated viruses (AAV) represent highly attractive gene therapy vectors and potent research tools for the modulation of gene expression in animal models or difficult-to-transfect cell cultures. Engineered variants, comprising chimeric, mutated or peptide-inserted capsids, have strongly broadened the utility of AAVs by altering cellular tropism, enabling immune evasion, or increasing transduction efficiency. In this work, the performance of 50 of the most used, predominantly published,...	pmid:36097758 doi:10.1089/hum.2022.109	Tue, 13 Sep 2022 06:00:00 -0400

	NCT Number	Title	Authors	Description	Identifier	Dates
65	pubmed:36097784	m6A modification of mRNA in skin diseases	Zhuoxian Yan Pengfei Liang	N6-methyladenosine (m6A) is the predominant post-transcriptional modification for eukaryotic mRNA. It's regulated by methyltransferases, demethylases, and m6A binding proteins, and plays an important role in regulating splicing, translation, and degradation of mRNA. Skin diseases, especially immune skin diseases and skin tumors, have a complicated pathogenesis and are refractory to treatment, seriously affecting the patient quality of life. Recent studies have revealed that m6A and its...	pmid:36097784 doi:10.11817/j.issn.1672-7347.2022.210332	Tue, 13 Sep 2022 06:00:00 -0400
66	pubmed:36097803	PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients	Ju Won Kim Ah Reum Lim Ji Young You Jung Hyun Lee Sung Eun Song Nam Kwon Lee Seung Pil Jung Kyu Ran Cho Cheol Yong Kim Kyong Hwa Park	CONCLUSION: Patients with HER2+ breast cancer with activating PIK3CA mutations had lower pCR rates and shorter PFS with palliative HER2-targeted therapy than those with wild-type PIK3CA. Precise targeted-therapy is needed to improve survival of patients with HER2+/PIK3CAm breast cancer.	pmid:36097803 doi:10.4143/crt.2022.221	Tue, 13 Sep 2022 06:00:00 -0400
67	pubmed:36097834	Generation and Application of Directly Reprogrammed Endothelial Cells	Cholomi Jung Jee Eun Oh Sangho Lee Young-Sup Yoon	Cell-based therapy has emerged as a promising option for treating advanced ischemic cardiovascular disease by inducing vascular regeneration. However, clinical trials with adult cells turned out disappointing in general. As a newer approach, direct reprogramming has emerged to efficiently generate endothelial cells (ECs), which can promote neovascularization and vascular regeneration. This review provides recent updates on the direct endothelial reprogramming. In general, directly reprogrammed...	pmid:36097834 doi:10.4070/kcj.2022.0190	Tue, 13 Sep 2022 06:00:00 -0400
68	pubmed:36097900	Clinicopathological features and HER2 expression of metaplastic squamous cell carcinoma of the breast	B B Gao Q Zheng L Yu D J Luo X Nie X Xu	Objective: To investigate the clinicopathological features and HER2 expression of metaplastic squamous cell carcinoma (MSCC) of the breast. Methods: A total of 47 MSCC cases diagnosed in the Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China from January 2010 to December 2021 were reviewed. The clinical information (including the follow-up data of HER2 positive patients) and pathological features were collected and analyzed. Results: All of...	pmid:36097900 doi:10.3760/cma.j.cn112151-20220430-00356	Tue, 13 Sep 2022 06:00:00 -0400
69	pubmed:36097955	Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression	Matthias Zadory Elliot Lopez Samuel Babity Simon-Pierre Gravel Davide Brambilla	Exogenously delivered mRNA-based drugs are emerging as a new class of therapeutics with the potential to treat several diseases. Over the last decade, advancements in the design of non-viral delivery tools have enabled mRNA to be evaluated for several therapeutic purposes including protein replacement therapies, gene editing, and vaccines. However, in vivo delivery of mRNA to targeted organs and cells remains a critical challenge. Evaluation of the biodistribution of mRNA vehicles is of utmost...	pmid:36097955 doi:10.1039/d2bm00859a	Tue, 13 Sep 2022 06:00:00 -0400

	NCT Number	Title	Authors	Description	Identifier	Dates
70	pubmed:36097977	Impact of tumoral structure and bacterial species on growth and biodistribution of live bacterial therapeutics in xenografted tumors	Maiko Takahashi Erike Widyasari Sukowati Shoko Nomura Akari Kato Kenji Mizuseki Yasuyoshi Watanabe Hidefumi Mukai	Live bacterial therapeutics is gaining attention, especially for cancer therapy, because anaerobic bacteria selectively grow inside the solid tumors. However, the effect of tumor structure and bacterial characteristics on the pharmacokinetics of tumors is unclear; therefore, we aimed to elucidate the effects of tumor structure and types of bacteria on tumoral bacterial growth. Using six mouse xenograft models, including stroma-rich tumors similar to clinical tumors, and two models of live...	pmid:36097977 doi:10.1080/1061186X.2022.2122477	Tue, 13 Sep 2022 06:00:00 -0400
71	pubmed:36098029	Characterising frailty, metrics of continuous glucose monitoring, and mortality hazards in older adults with type 2 diabetes on insulin therapy (HARE): a prospective, observational cohort study	Erik Fung Leong-Ting Lui Lei Huang King Fai Cheng Gloria H W Lau Yi Ting Chung Behzad Nasiri Ahmadabadi Suyi Xie Jenny S W Lee Elsie Hui Wing Yee So Joseph J Y Sung Irwin King William B Goggins Queenie Chan Marjo-Riitta Järvelin Ronald C W Ma Elaine Chow Timothy Kwok	BACKGROUND: To our knowledge, no previous study has examined the inter-relationship between frailty, dysglycaemia, and mortality in frail older adults with type 2 diabetes who are on insulin therapy. We used continuous glucose monitors (CGMs) to profile this patient population and determine the prognostic value of CGM metrics. We hypothesised that incremental frailty was associated with increased hypoglycaemia or time below range (TBR).	pmid:36098029 doi:10.1016/S2666-7568(21)00251-8	Tue, 13 Sep 2022 06:00:00 -0400
72	pubmed:36098037	Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial	Yoshihito Kogure Shunichiro Iwasawa Hideo Saka Yoichiro Hamamoto Akiko Kada Hiroya Hashimoto Shinji Atagi Yuichi Takiguchi Noriyuki Ebi Akira Inoue Takayasu Kurata Isamu Okamoto Masafumi Yamaguchi Toshiyuki Harada Masahiro Seike Masahiko Ando Akiko M Saito Kaoru Kubota Mitsuhiro Takenoyama Takashi Seto Nobuyuki Yamamoto Akihiko Gemma	BACKGROUND: In Japan, docetaxel, a cytotoxic monotherapy, is the standard drug administered to older patients with advanced non-small-cell lung cancer (NSCLC). Carboplatin plus nab-paclitaxel has shown a high objective response rate in patients with squamous histology and was suggested to improve overall survival in patients aged 70 years and older. The CAPITAL trial aimed to assess the safety and efficacy of carboplatin plus nab-paclitaxel versus docetaxel as first-line therapy for patients...	pmid:36098037 doi:10.1016/S2666-7568(21)00255-5	Tue, 13 Sep 2022 06:00:00 -0400